List of Implants Companies in California - 61

Advanced Bifurcation Systems Inc. has developed a novel technology to enable effective stenting of coronary arteries at their branch points (bifurcations). This comprehensive platform is a paradigm shift in interventional cardiology that will reduce the need for open-heart surgery, hospitalizations, and repeat coronary angioplasties. The technology will simplify procedures and improve outcomes while reducing angioplasty times which results in significant improvement to the overall patient care at a reduced cost.

AB is proud to be the only U.S. based manufacturer of cochlear implants and equally proud to be a part of the larger Sonova group. At AB, success begins with a passion for hearing restoration and is driven by our global workforce of over a thousand employees. For more than 25 years, AB has removed limitations for those otherwise isolated from the world of sound. Always focused on bringing meaningful change through innovative technology, AB has set the standard for performance, lifestyle support, and access to sound in the field of cochlear implantation. Having implanted over 100,000 ears in over 130 countries and established a track record for developing high-performing, state-of-the-art products, our team of talented scientists, engineers, audiologists and other professionals are driven to succeed, work with integrity, and stay firmly committed to quality. Sonova companies include brands focused on hearing aids, cochlear implants, wireless communications, and clinical service. Together, we strive to create a world where everyone enjoys the delight of hearing and lives a life without limitations.Advanced Bionics is a global leader providing solutions for severe-to-profound hearing loss.

With a complete platform of core trauma and extremity products, AOS has become a trusted leader with its entire focus on the orthopaedic trauma industry. Relying on the professional guidance of the four original founding partners, as well as the clinical expertise and training of skilled surgeon champions, AOS designs and manufactures innovative orthopaedic trauma products with intra-operative and postoperative clinical benefits. AOS’s products are distributed worldwide through independent distributors and agents. By continuing to build strong relationships with our valued distribution network and surgeon users, AOS continues to improve every aspect of the way we do business. Especially for our patients and their families worldwide.

Alessa Therapeutics is a biotechnology company that specializes in developing localized treatments for solid organ disease.

Alpha Medical Instruments,developer, manufacturer, Balloon flotation catheters, venous catherization, right heart, measurements, venous, pulmonary artery pressures, cardiac output

The mission of Alume Biosciences is to make our proprietary nerve illumination technology available for surgeons so that patients everywhere can benefit. Learn how you can help us move surgery into the light.

In neuroscience, where so much is yet to be explored, it’s crucial that scientists and researchers can devote their time to discovery. Through a partnership with a team of experts at Amuza, researchers gain access to precise tools that get data right the first time and opens the door to discovery. Amuza is a researcher-focused company. We provide instruments and support to improve productivity and outcomes for life science research and the quality of human life.

Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Autonomic Technologies is a medical device company that focuses on the development and commercialization of innovative therapies for autonomic disorders, particularly severe headaches.

Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms

Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs. To learn more, visit www.betabionics.com. For safety information, visit: www.betabionics.com/safety.

Caldera Medical is a medical device company solely focused on women's health with a commitment to our mission of "Improving the Quality of Life for Women!" We develop, build and market best in class surgical products for the treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse. Working closely with surgeons to help those here at home, as well as women around the world, through our humanitarian programs to give them the access to the education and treatment they deserve. Mission - To Improve the Quality of Life for Women Vision - To be the Global Leader in Women's Pelvic Health Values "C4"​ - Care / Collaborate / Challenge / Create

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

CompactCath is a medical device company committed to improving the quality of life for self-catheterizing patients, their families, and healthcare providers. Designed and founded at Stanford University by a team of physicians, engineers, and catheter users, we are driven by a goal to design medical devices that enable those with chronic conditions to lead active, thriving, independent lives. CompactCath, our flagship intermittent urinary catheter, is a revolutionary pre-lubricated, non-touch catheter for users looking for a compact, discreet, and easy to use solution that fits seamlessly in their lives. CompactCath is FDA cleared in the US and CE approved in Europe. For more information, visit our website: www.compactcath.com and watch our video: https://www.youtube.com/watch?v=k8cjjgfGhAY

ConKay Medical Systems is an early-stage medical device company advancing unique solutions to treat valvular regurgitation in patients with progressive heart failure. Valvular regurgitation is when your valves do not close properly allowing blood to flow backwards in your heart causing shortness of breath, chest pain, and sometimes death. There are over 100 million people currently affected globally with valvular disease and an additional 5M Americans are diagnosed each year. ConKay's annular repair technology is designed to treat the main cause of functional regurgitation leaving the healthy leaflets intact to perform the way it was intended. We are currently focused on the Tricuspid valve. Message us for more information!

Delpor is a clinical stage life sciences company that utilizes innovative drug-delivery technologies in order to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone (drug/device combination product) for the treatment of schizophrenia. Delpor is also pursuing 6-12 month formulations of other drugs targeting CNS conditions including Neuromuscular Diseases, Neurodegenerative Diseases, Addiction, and other disorders.

EchoPixel is building a new world of patient care with its interactive, 3D medical visualization software. The True 3D system allows medical professionals to interact with patient-specific organs and tissue in an open 3D space emanating from a display, enabling doctors to immediately identify, evaluate, and dissect clinically significant structures. In diagnostic, surgical planning and image guided treatment applications, EchoPixel is a privately held, venture backed company located in Santa Clara, CA.

Elixir Medical is committed to transforming care of patients with heart and vascular disease through innovation. Since 2005, the company has continually sought to improve the treatment of vascular disease with: - Drug-eluting coronary stent systems (DES) - Fully resorbable drug-eluting scaffold systems (BRS) - Drug-eluting coronary bioadaptor systems Its latest innovation — the DynamX™ Coronary Bioadaptor System — is designed to be a significant advancement beyond drug-eluting stents (DES). Elixir Medical’s innovations are designed to make a meaningful change in patients’ lives. The company does not simply want to engineer a better medical device. Saving lives and helping patients enjoy their daily life is what drives us every day.

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Empirical Spine, Inc., is focused on developing disruptive solutions for the surgical treatment of spinal disorders, in order to deliver superior clinical outcomes while lowering overall healthcare costs. We are building a new standard in spine surgery that works in parallel with the natural structures of the spine to restore functionality and optimize quality of life by creating a new category called Dynamic Sagittal TetherTM (DST). For patients with mobile degenerative spondylolisthesis, LimiFlexTM is the first and only Dynamic Sagittal Tether that restores the natural motion and stability required after a decompression by augmenting the posterior tension band, creating elastic resistance to flexion and maintaining lordosis, and offers the potential for significant reduction in cost, invasiveness, and sequelae compared to spinal fusion. The U.S. pivotal trial on our breakthrough LimiFlex Dynamic Sagittal Tether is fully enrolled and nearing its two-year endpoint. In summer 2022, we expect to submit results from this trial to the FDA for PMA approval. Follow our LinkedIn page for company news and updates. For more information about LimiFlex Dynamic Sagittal Tether visit the following website: https://www.limiflex.com/. Caution: The LimiFlex DST is an investigational device in the U.S. and is limited by law to investigational use.

ENCOLL CORP. is a medical devices company based out of 4576 ENTERPRISE STREET, FREMONT, California, United States.

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. We have a therapeutic portfolio designed to treat diseases which currently have clinically relevant unmet needs. Our existing products can treat a wide spectrum of vascular disease through abdominal aortic aneurysms to lower limb peripheral vascular disease. We obtain excellent clinical outcomes through meticulous attention to product design, manufacturing, and training, all backed by industry-leading clinical evidence. With a robust pipeline of disruptive technology, our vision is to provide physicians with the best device for each patient; because when it comes to ensuring patient well-being, we are never satisfied with the status quo.

Our mission is to improve the lives of stroke victims suffering from difficulty with movement and coordination. Standard rehabilitation can help a patient recover some muscle function. However, mild electrical brain stimulation, when administered in conjunction with muscle training, has been shown in published research studies to significantly improve a patient's ability to move, resulting in often dramatic improvements to quality of life, when compared to muscle training alone. The EPIC Stimulator is a tiny leadless device that provides short low-energy electric pulses directly to the cortex. The implant procedure is very simple (~15 min). The EPIC contains no battery and is externally powered through a comfortable cap. The cap is only worn by the patient during muscle training (about an hour a day for 3 months). After all rehab is complete, the EPIC devices can be easily removed if desired. In addition to mild brain stimulation, the EPIC allows the recording of a patient's EEG, which is streamed to a handheld device and then to the cloud. This allows neurological changes in the brain to be tracked and quantified. Note, the EPIC is not approved by the FDA for human use. It is only for investigational use as part of a clinical trial.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

March 20,2023 CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc. CalciMedica’s stock will commence trading on March 21, 2023 on the Nasdaq Global Market under the trading symbol “CALC”. Immediately prior to the closing of the merger, CalciMedica completed the previously announced private placement of $10.3 million. With the closing of the merger, CalciMedica has approximately $34 million in cash and cash equivalents, which is expected to provide the company a cash runway into the second half of 2024 and fund the advancement of Auxora through clinical milestones in 2023,

XENT was acquired by MDT on 5/13/2022 Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that. InterVene was originally a product of the Stanford Biodesign Fellowship and is a former Company In Residence at the Fogarty Institute for Innovation. InterVene's offices are now located in South San Francisco near SFO airport.

JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.

Corneal Surgery Devices

The Lifewave solution will establish a new standard-of-care for the guided-care of heart failure patients. Our solution consists of a digital AI-powered platform, and differentiated by a medical radar lung sensor that is non-invasive, simple-to-use, low cost, and provides a direct and absolute measurement of lung fluid for guiding care.

MedSpark is a medical technology company that specializes in developing innovative medical devices.

Implantable Shock Absorbers for Knee OA

Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The system is highly capable and easily upgradeable, providing a menu of therapy options.

Natus Medical Incorporated (Natus) offers medical equipment, software, supplies and services for the diagnosis, monitoring, and treatment of impairments and disorders effecting the brain, neural pathways, and eight sensory nervous systems. Our comprehensive product portfolio represents a heritage of innovation and leadership. Natus brands have been setting the standard for patient care for over eighty (80) years. Our products are trusted by medical professionals in university medical centers, hospitals, private practices, clinics and research laboratories around the world. Natus does not endorse personal/non-work related comments made by employees on social media. Further, Natus values the respect and inclusion of all people without regard to race, color, religion, sex, national origin, veteran status, disability, sexual orientation, gender identity, or any other protected status.

At Neuralace Medical, we are driven to accelerate the world's transition to sustainable, non-invasive chronic pain relief. What do we believe that very few others do? We fundamentally believe that overcoming chronic pain is inevitable. With our bold vision, we are challenging the conventional thinking the healthcare industry is currently laden with to implement innovations and technological advances to improve the overall quality of life of individuals by maximizing pain relief and minimizing side-effects, redefining the very concept of pain therapy which can leave patients with more side-effects than benefits. NeuraLace is not just a device developer, but also a technology company with a focus on medical innovations that can significantly restore the quality of life patients suffering from chronic pain. Our inherent interest in innovation and deep technical knowledge, along with the partnerships we are currently developing, will allow us to realize our vision and create something truly special. We are a startup medical technology company here to make a dent in the world of pain therapeutics!

Neuralink is a team of exceptionally talented people. We are creating the future of brain-machine interfaces: building devices now that will help people with paralysis and inventing new technologies that will expand our abilities, our community, and our world. Our goal is to build a system with at least two orders of magnitude more communication channels (electrodes) than current clinically-approved devices. This system needs to be safe, it must have fully wireless communication through the skin, and it has to be ready for patients to take home and use on their own. Our device, called the Link, will be able to record from 1024 electrodes and is designed to meet these criteria.

Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urgency Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera's minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.

Pinnacle Spine Group is dedicated to the design, development, manufacturing and marketing of innovative best-in-class spinal implants and instruments that offer greater opportunities for positive patient outcomes. We are committed to providing surgeons increased control, flexibility and choices when it comes to implants, instrumentation and autograft delivery, providing a better experience for surgeons and their staff so they can better serve their patients.

Presbia is a medical device company focused on the development of the presbyopia-correcting Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.

Profusa's mission is to make our body's chemistry easily accessible to improve health and wellness. We are dedicated to becoming a leader in the development of real-time biosensors that provide unprecedented insights into our overall health status. We are leading the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Our technology enables the development of bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use. Profusa's first clinical offering, the Lumee Oxygen Platform™, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. It may be used in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. Any questions? Please visit profusa.com or email us at info@profusa.com

R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD is the narrowing or blockage of the vessels that carry blood from the heart to the legs or lower extremities; it is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can happen in any blood vessel, but it is more common in the legs than the arms. It affects 200 million people globally. Approximately 6.5 million people at the age of 40 and older in the United States have PAD. These numbers continue to rise given the increasing burden of risk factors and an aging population. If a patient has PAD, they are at risk for developing coronary artery disease and cerebrovascular disease, which could lead to a heart attack or stroke as well. The R3 Vascular BVS platform combines the best of both worlds of BTK therapy, designed to deliver the ‘stent-like' support of a scaffold, along with the anti-inflammatory result of sirolimus, but ‘disappearing' over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.

Regenerative Patch Technologies LLC (RPT) is a CA-based biotechnology company focused on the development of stem cell-based therapies designed to reverse blindness caused by advanced dry age related macular degeneration (AMD).

ReShape Lifesciences Inc. is America's premier weight-loss and metabolic health-solutions company, offering an integrated approach to managing and treating obesity. The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The recently launched 𝗋𝖾𝗌𝗁𝖺𝗉𝖾𝗰𝗮𝗿𝗲™ virtual health coaching program is a reimbursed, virtual tele-health, weight-management program that supports lifestyles changes for al weight-loss patients, to help them keep the weight off over time. Together, we will build a healthy life, one choice at a time.

RxSight® is an ophthalmic medical technology corporation headquartered in Aliso Viejo, California that has commercialized the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye.

Sayenza Bio is a leading clinical stage biotechnology company committed to improving patient lives by harnessing the regenerative power of fat, the body’s largest source of stem cells, for limitless aesthetic and regenerative medicine applications. At Sayenza, our passionate, doctor-driven team unites cutting-edge scientific innovation with vast commercial expertise, propelling us towards transformative breakthroughs in healthcare. With a strong leadership team in place, extensive publications in leading journals, and top-tier KOLs signing up as early adopters, NESVF™ and Liquid Gold Graft™ are poised to become gold standards for stem cell and fat grafting applications and take a large chunk of the $6.25 billion aesthetics market.

We are reimagining eyecare with transformative technology and an interventional mindset. We believe interventions should happen sooner to preserve, protect, or restore natural eye function. So, we aim to provide eyecare providers with transformative, clinically-proven therapies that are intuitive, less invasive, and more intelligent.

SigmaGraft®, based in Fullerton, California, USA, collaborates with the world's leading clinicians and researchers to innovate products and build clinical experience. Our products are registered and sold worldwide, and they include bone grafting products for bone regeneration, membrane products for tissue regeneration, and more.

Silver Bullet Therapeutics is an early stage company dedicated to the treatment of osteomyelitis. Through the use of proprietary implants that can be placed using local anesthesia and minimal sedation, the duration of exposure to long-term intravenous antibiotic will be shortened.

Simplify Medical is a medical devices company specializing in clinically effective spine technology for the cTDR procedure segment.

Founded in 2003, Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

STAAR Surgical Company (an S&P 400 midcap company trading under NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 35 years. The company offers the EVO Visian implantable Collamer® lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer Lens or "ICL"​. Over 1,00,000 Visian ICLs have been implanted to date. It also provides minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece Collamer aspheric optic; and Toric IOLs for cataract patients, as well as preloaded injectors for use in cataract surgery. In addition, the company sells surgical products, and other related instruments and devices, as well as injector parts; and manufactures AquaFlow devices for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health organizations, group purchasing organizations, and government facilities primarily under the STAAR, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow trademarks. The company sells products directly through its sales representatives and independent distributors in more than 75 countries. STAAR Surgical Company was founded in 1982 and is headquartered in Lake Forest, California. Its manufacturing plant is located in Monrovia, CA.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2023 Sales: $20.5 billion ● Industry: Medical Instruments & Supplies ● Employees: 52,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.4 billion spent on research and development in 2023 ● ~12,900 patents owned globally in 2023 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296

Subsense is a neurotechnology company developing the first non-surgical, nanoparticle-based bidirectional brain-computer interface. Subsense is partnered with leading global neurological research institutions. The company is venture-backed with its global headquarters in Palo Alto, California.

Repair Mesh

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

Delivering the latest innovation in sacroiliac joint surgical solutions, Tenon Medical is uniquely positioned to introduce a refined surgical option for patients with chronic sacroiliac joint pain that fail conservative care. The Catamaran™ SIJ Fusion System offers a patented new surgical solution that places a single implant directly into the SI joint. Tenon Medical is led by a powerful team with years of cumulative experience in designing and launching innovative surgical solutions that deliver a pathway to improved quality of life for thousands of patients.

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

At ViewRay, our vision is clear: conquer cancer by re-envisioning radiation therapy., giving doctors new and better ways to treat their patients. ViewRay®, Inc. (NASDAQ:VRAY) shifts the paradigm in cancer treatment with the MRIdian® MRI-guided adaptive radiotherapy system. We're changing radiation therapy for the better with accurate, precise and personalized cancer treatment that no other system delivers, addressing the key limitations of existing external-beam radiation therapy technologies. Real-time imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian shapes the dose to fit the day. It's the only MR solution that enables fully integrated adaptive treatment with complete, on-table re-optimization of the daily treatment plan. It knows when to strike – and when to stop. MRIdian is the only RT solution with automated beam gating for precise and accurate dosing. When the tumor moves, the beam stops. The result? Better outcomes for patients. After seven years of clinical use, MRIdian has treated more than 12,500 patients worldwide. We're an innovative, entrepreneurial company with big ambitions, unlimited potential and a passion for a culture that is diverse and committed to our physicians and their patients. If you're ready to change the way the world views cancer, come join our team.

Developing miniaturized, long-term biopharmaceutical implants to reduce medication adherence challenges.

Zeda is a leading technology solutions company. Our objective is to better lives by investing in cutting-edge technologies, innovative companies, and groundbreaking ideas. Our foundation combines expertise from diverse industries, including AM, nanotech, precision manufacturing, and incubating new ideas. From life-changing medical devices to the foremost advancements in space, our mission is to build it all better together.